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General Information.  1H and 13C NMR spectra were recorded on a Varian, Inc. UNITY 
INOVA instrument operating at 500 MHz using D2O or DMSO-d6 as the solvent.  1H 
NMR data are reported as follows:  s, singlet; d, doublet; t, triplet; q, quartet; m, 
multiplet; br s, broad singlet; dd, doublet of doublets.  High-resolution mass spectra 
(FAB) were recorded on a JMS-600H double-focusing, high-resolution, magnetic sector 
mass spectrometer at the Mass Spectrometry Laboratory, Division of Chemistry and 
Chemical Engineering, California Institute of Technology.  Column chromatography was 
carried out on silica gel (40-63 µm, EM Science).  Analytical HPLC was performed using 
a Vydac C18 column (5 mm, 4.5 x 250 mm) with buffer A (5 mM NH4OAc, pH 5.5 with 
10% acetonitrile) and buffer B (5 mM NH4OAc, pH 5.5 with 90% acetonitrile); a linear 
gradient of 100% buffer B in 50 min was used with a flow rate of 1 mL/min.  All reagents 
were of highest available commercial quality and were used without further purification.  
Puromycin aminonucleoside (3’-amino-3’-deoxy-N, N’-dimethyl-adenosine) (PANS) was 
purchased from Sigma Chemical Co.  FMOC-(4-methoxy-D-phenylalanine) and FMOC-
(D-alanine) were purchased from Bachem.  FMOC-(4-methyl-L-phenylalanine), FMOC-
(L-alanine), and FMOC-(L-β-homoalanine) were purchased from Fluka.  FMOC-(4-
 2
methyl-D-phenylalanine) and FMOC-(4-methyl-L-β-phenylalanine) were from Peptech.  
Puromycin and puromycin analog concentrations were determined with the following 
extinction coefficients (M-1cm-1) at 260 nm:  L- and D-puromycin (1a and 1b) [ε = 
11,790] in H2O; L-(4-Me)-Phe-PANS, D-(4-Me)-Phe-PANS, and L-β-(4-Me)-Phe-PANS 
(2a – 2c) [ε = 10,500] in H2O; and L-Ala-PANS, D-Ala-PANS, and L-β-Ala-PANS (3a – 
3c) [ε = 11,000] in phosphate buffered saline (pH 7.3). 
Rabbit reticulocyte lysate was purchased from Novagen.  Rabbit globin mRNA 
was obtained from Life Technologies Gibco BRL.  L-Puromycin (1a) was purchased 
from Sigma Chemical Co.  Ras mRNA was prepared by using two DNA primers 
complementary to the 5’- and 3’-ends of the coding region for H-Ras (pProEX HTb 
vector, a kind gift from Dafna Bar-Sagi)1 to amplify the gene using PCR.  mRNA was 
produced by T7 runoff transcription2 of the H-Ras DNA in the presence of RNAsecure 
(Ambion) followed by gel purification via denaturing urea-PAGE and ‘crush and soak’ 
RNA isolation.  L-[35S]methionine (1,175 Ci/mmol) was purchased from NEN Life 
Science Products.  Carboxypeptidase Y was obtained from Pierce.  GF/A glass microfiber 
filters were from Whatman.  Scintillation counting was carried out using a Beckman LS-
6500 liquid scintillation counter. 
General Procedure for Preparation of Puromycin Analogs.  N, N’-
dicyclohexylcarbodiimide (DCC) (0.0539 mmol) was added to a cold (0 °C) solution of 
PANS (0.0520 mmol), FMOC-protected amino acid (0.0541 mmol), and N-
hydroxysuccinimide (NHS) (0.0556 mmol) in dried N,N’-dimethylformamide (DMF) 
(0.900 mL).  The solution was stirred for 30 min in an ice-water bath and then for 25 h at 
ambient temperature.  N,N’-dicyclohexylurea was filtered and washed (EtOAc, 4 mL), 
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and the filtrate was concentrated in vacuo.  For 1b, the residue was resuspended in 
EtOAc, sonicated, and the mixture was filtered and then dried.  The material was purified 
by gradient flash chromatography using CHCl3 0H2+&+&O3 (4:96) for 1b or 
MeOH/CHCl3 (7:93) for 2a-2c and 3a-3c.  Homogenous product fractions were dried in 
vacuo to yield the FMOC-protected product.  FMOC-deprotection was carried out in 20% 
(v/v) piperidine in DMF (5mL) with stirring for 30 min at ambient temperature.  The 
solvent was removed in vacuo and the residue was subjected to gradient flash 
chromatography using CHCl3 0H2+&+&O3 (8:92) for 1b, 2a, and 2b and 
TEA/MeOH/CHCl3 (2:10:88) for 2c and 3a-3c to afford the titled products.  
Confirmation of purity was assessed using analytical HPLC. 
9-{3’-Deoxy-3’-[(4-methoxy-D-phenylalanyl)amino]-β-D-ribofuranosyl}-6-
(N,N’-dimethylamino)purine (D-puromycin) (1b).3  White solid (31.5 mg, 87.3%):  1H 
(DMSO-d6) δ 1.85 ( br s, 2H), 2.58-2.63 (m, 1H), 2.93 (dd, J = 4.5, 14 Hz, 1H), 3.42 (dd, 
J = 4.5, 8.5 Hz, 2H), 3.51-3.56 (m, 2H), 3.72 (s, 6H), 3.93-3.96 (m, 1H), 4.47-4.51 (m, 
4H), 5.17 (t, J = 5.5 Hz, 1H), 5.97 (d, J = 2.0 Hz, 1H), 6.17 (d, J = 5.0, 1H), 6.85 (d, J = 
9.0 Hz, 2H), 7.15 (d, J = 8.5 Hz, 2H), 8.08 (br s, 1H), 8.24 (s, 1H), 8.45 (s, 1H); 13C 
(DMSO-d6) δ 25.4, 50.6, 56.0, 56.8, 61.7, 73.8, 84.4, 90.2, 114.3, 131.0, 138.7, 150.4, 
152.6, 158.0, 175.5; HRMS (FAB), m/z calculated for C22H30N7O5 (M+H)+ 472.2311, 
found 472.2307. 
9-{3’-Deoxy-3’-[(4-methyl-L-phenylalanyl)amino]-β-D-ribofuranosyl}-6-
(N,N’-dimethylamino)purine [L-(4-Me)-Phe-PANS] (2a).  Pale white solid (18.8 mg, 
80.8%):  1H NMR (DMSO-d6) δ 1.84 (br s, 2H), 2.26 (s, 6H), 2.52-2.57 (m, 1H), 2.94 
(dd, J = 4.5, 14 Hz, 1H), 3.44-3.52 (m, 2H), 3.67-3.70 (m, 2H), 3.92-3.95 (m, 1H), 4.44-
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4.50 (m, 4H), 5.14 (t, J = 5.5 Hz, 1H), 5.98 (d, J = 3.0 Hz, 1H), 6.14 (d, J = 4.0 Hz, 1H), 
7.10 (dd, J = 8.0, 18 Hz, 4H), 8.07 (d, J = 5.5 Hz, 1H), 8.24 (s, 1H), 8.45 (s, 1H); 13C 
(DMSO-d6) δ 21.3, 41.2, 50.7, 56.9, 61.7, 73.9, 84.3, 90.2, 120.3, 129.4, 129.8, 135.7, 
136.3, 138.7, 150.4, 152.6, 155.0, 175.5; HRMS (FAB), m/z calculated for C22H30N7O4 
(M+H)+ 456.2362, found 456.2367. 
9-{3’-Deoxy-3’-[(4-methyl-D-phenylalanyl)amino]-β-D-ribofuranosyl}-6-
(N,N’-dimethylamino)purine [D-(4-Me)-Phe-PANS] (2b).  Pale white solid (20.7 mg, 
88.8%):  1H NMR (DMSO-d6) δ 1.85 (br s, 2H), 2.26 (s, 6H), 2.61 (dd, J = 8.0, 13 Hz, 
1H) 2.96 (dd, J = 4.5, 14 Hz, 1H), 3.42-3.45 (m, 1H), 3.51-3.56 (m, 1H), 3.71-3.73 (m, 
2H), 3.94-3.96 (m, 1H), 4.40-4.49 (m, 4H), 4.48 (d, J = 12 Hz, 1H), 5.17 (t, J = 5.5 Hz, 
1H), 5.97 (d, J = 2.5 Hz, 1H), 6.19 (br s, 1H), 7.11 (dd, J = 8.0, 16 Hz, 4H), 8.10 (br s, 
1H), 8.23 (s, 1H), 8.45 (s, 1H); 13C (DMSO-d6) δ 21.4, 41.0, 50.6, 56.8, 61.7, 73.8, 84.4, 
90.2, 120.3, 129.4, 129.9, 135.8, 136.1, 138.7, 150.4, 152.6, 155.0, 175.5; HRMS (FAB), 
m/z calculated for C22H30N7O4 (M+H)+ 456.2362, found 456.2360. 
9-{3’-Deoxy-3’-[(4-methyl-L-β-phenylalanyl)amino]-β-D-ribofuranosyl}-6-
(N,N’-dimethylamino)purine [L-β-(4-Me)-Phe-PANS] (2c).  Pale white solid (17.8 mg, 
73.0%):  1H NMR (D20) δ 2.06 (s, 6H), 2.45-2.49 (m, 1H), 2.67 (d, J = 6.5 Hz, 1H), 3.18 
(t, J = 6.0 Hz, 1H), 3.28 (br s, 3H), 3.37-3.39 (m, 1H), 3.49-3.50 (m, 1H), 3.59-3.62 (m, 
1H), 3.80 (dd, J = 2.0, 13 Hz, 1H), 4.08-4.10 (m, 1H), 4.35 (dd, J = 6.0, 8.5 Hz, 1H), 4.46 
(dd, J = 3.0, 5.5 Hz, 1H), 5.94 (d, J = 2.5 Hz, 1H), 7.03 (s, 4H), 8.03 (s, 1H), 8.15 (s, 1H); 
13C NMR (D20) δ 19.1, 26.0, 40.5, 49.8, 50.5, 54.5, 60.8, 73.6, 82.7, 89.7, 111.0, 120.0, 
129.4, 129.6, 134.0, 137.2, 138.0, 148.8, 152.3, 173.6; HRMS (FAB), m/z calculated for 
C23H32N7O4 (M+H)+ 470.2519, found 470.2508. 
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9-{3’-Deoxy-3’-[(L-alanine)amino]-β-D-ribofuranosyl}-6-(N,N’-
dimethylamino)purine (L-Ala-PANS) (3a).  Pale yellow solid (5.7 mg, 30.2%):  1H 
NMR (D2O) δ 1.41 (d, J = 7.0 Hz, 3H), 3.28 (br s, 6H), 3.63 (dd, J = 3.5, 13 Hz, 1H), 
3.82 (dd, J = 2.5, 13 Hz, 1H), 3.97 (q, J = 7.0 Hz, 1H), 4.17-4.18 (m, 1H), 4.55-4.58 (m, 
2H), 4.62-4.64 (m, 1H), 5.98 (d, J = 3.0 Hz, 1H), 8.03 (s, 1H), 8.17 (s, 1H); 13C NMR 
(D2O) δ 17.3, 39.0, 49.4, 51.0, 60.7, 73.5, 82.7, 89.6, 119.5, 138.0, 148.8, 152.2, 154.6, 
172.4; HRMS (FAB), m/z calculated for C15H24N7O4 (M+H)+ 366.1892, found 366.1889. 
9-{3’-Deoxy-3’-[(D-alanine)amino]-β-D-ribofuranosyl}-6-(N,N’-
dimethylamino)purine (D-Ala-PANS) (3b).  Pale yellow solid (8.6 mg, 45.4%):  1H 
NMR (D20) δ 1.43 (d, J = 7.5 Hz, 3H), 3.28 (br s, 6H), 3.65 (dd, J = 4.0, 13 Hz, 1H), 3.83 
(dd, J = 2.5, 13 Hz, 1H), 4.02 (q, J = 7.5 Hz, 1H), 4.14-4.17 (m, 1H), 4.55-4.58 (m, 2H), 
4.64-4.66 (m, 1H), 5.98 (d, J = 3.0 Hz, 1H), 8.04 (s, 1H), 8.17 (s, 1H); 13C NMR (D20) 
δ 17.0, 39.0, 49.3, 50.9, 60.8, 73.3, 82.8, 89.6, 106.0, 119.6, 138.1, 152.3, 154.8, 172.0; 
HRMS (FAB), m/z calculated for C15H24N7O4 (M+H)+ 366.1892, found 366.1898. 
9-{3’-Deoxy-3’-[(L-β-homoalanine)amino]-β-D-ribofuranosyl}-6-(N,N’-
dimethylamino)purine (L-β-Ala-PANS) (3c).  Pale yellow solid (4.6 mg, 25.6%):  1H 
NMR (D20) δ 1.16 (d, J = 6.5 Hz, 3H), 1.74 (s, 1H), 2.52 (d, J = 3.5 Hz, 2H), 3.24 (br s, 
6H), 3.52-3.61 (m, 2H), 3.78 (d, J = 13 Hz, 1H), 4.11 (d, J = 5.5 Hz, 1H), 4.62-4.64 (m, 
2H), 5.93 (s, 1H), 7.99 (s, 1H), 8.13 (s, 1H); 13C NMR (D20) δ 18.2, 39.0, 39.5, 45.0, 
50.7, 60.7, 73.5, 82.7, 89.6, 119.5, 138.0, 148.8, 152.2, 172.7; HRMS (FAB), m/z 
calculated for C16H26N7O4 (M+H)+ 380.2049, found 380.2054. 
IC50 Determination.  Translation reactions containing [35S]Met were made up in 
batch on ice and added in aliquots to microcentrifuge tubes containing an appropriate 
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amount puromycin or puromycin analog dried in vacuo.  Typically, a 20 µl translation 
mixture consisted of 0.8 µL of 2.5 M KCl, 0.4 µL of 25 mM MgOAc, 1.6 µL of 12.5X 
Translation Mixture without methionine (25 mM dithiothreitol (DTT), 250 mM HEPES 
(pH 7.6), 100 mM creatine phosphate, and 312.5 µM of 19 amino acids, except 
methionine), 3.6 µL of nuclease-free water, 0.6 µL (6.1 µCi) of [35S]Met (1175 
Ci/mmol), 8 µL of Red Nova® nuclease-treated lysate, and 5 µL of 0.05 µg/µL globin 
mRNA.  Inhibitor, lysate preparation (include all components except template), and 
globin mRNA were mixed simultaneously and incubated at 30 ºC for 60 min.  Then 2 µL 
of each reaction was combined with 8 µL of tricine loading buffer (80 mM Tris-Cl (pH 
6.8), 200 mM DTT, 24% (v/v) glycerol, 8% sodium dodecyl sulfate (SDS), and 0.02 % 
(w/v) Coomassie blue G-250), heated to 90 ºC for 5 min, and applied entirely to a 4% 
stacking portion of a 16% tricine SDS-polyacrylamide gel containing 20% (v/v) glycerol4 
(30 mA for 1.5h).  Gels were fixed in 10% acetic acid (v/v) and 50% (v/v) methanol, 
dried, exposed overnight on a PhosphorImager screen, and analyzed using a Storm 
PhosphorImager (Molecular Dynamics).  Analysis in Figure S1 was carried out as 
described above except 6 µL of each reaction and 24 µL of tricine loading buffer were 
loaded (1.5-fold increase in stacking and resolving portion of gel; 30mA for 7 h). 
Carboxypeptidase Assay.  Translation reactions were prepared as described for 
IC50 determination except reactions (50 µL) contained 2 µL of 2.5 M KOAc, 1 µL of 25 
mM MgOAc, 4 µL of 12.5X Translation Mixture without methionine (25 mM 
dithiothreitol (DTT), 250 mM HEPES (pH 7.6), 100 mM creatine phosphate, and 312.5 
µM of 19 amino acids, except methionine), 16 µL (163 µCi) of [35S]Met (1175 Ci/mmol), 
20 µL of Red Nova® nuclease-treated lysate, and 6.96 µL of 230 µg/mL Ras mRNA.3  
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Inhibitor, lysate components, and Ras mRNA were mixed simultaneously and incubated 
at 30 ºC for 60 min.  Then 2 µL of reaction was combined with 150 µL of 0.1 M sodium 
acetate (pH 5.0) and 17 µL carboxypeptidase Y (CPY) (1 mg/mL in 0.05 M sodium 
citrate (pH 5.3) Pierce), and incubated at 37 ºC for 18 h.  After incubation, reactions were 
mixed with 100 µL of 1 N NaOH/2% H2O2 (hydrolyzes charged tRNAs and removes the 
red color that may quench scintillation counting) and incubated at 37 ºC for 10 min to 
hydrolyze the charged tRNAs.  Then 0.9 mL of 25% trichloroacetic acid (TCA)/2% 
casamino acids was added to the samples, vortexed, and put on ice for 10 min.  The 
samples were filtered on GF/A filters (pre-soaked in 5% TCA), washed 3 times with 3-
mL portions of cold 5% TCA, and scintillation counted to determine the amount of 
[35S]Met-Ras.  For the no CPY-treated samples, [35S]Met-Ras (2 µL of reaction) was 
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Figure S1.  (A) Tricine-SDS-PAGE analysis of globin fragments resulting from 
puromycin and puromycin analog attachment.  Lane 1, no template; lane 2, globin alone, 
no puromycin; lane 3, L-puromycin (2 µM); lane 4, D-puromycin (500 µM); lane 5, L-4-
Me)-Phe-PANS (2 µM); lane 6, D-(4-Me)-Phe-PANS (1500 µM); lane 7, L-β-(4-Me)-
Phe-PANS (1200 µM); lane 8, puromycin aminonucleoside (PANS) (5 mM).  PANS is a 
negative control molecule (no amino acid moiety) to evaluate the production of protein 
fragments in the presence of high exogenous molecule concentrations.  The globin 
fragment-puromycin complexes are indicated by brackets.  (B) Quantification of the 
globin fragment-puromycin complexes from A.   
 9
 














Figure S2.  Model for D-puromycin (red) placement in the 50S ribosomal-CCdA-p-L-
puromycin (blue) complex from Haloarcula marismortui (Nissen, P.; Hansen, J.; Ban, 
N., Moore, P. B.; Steitz, T. A. Science 2000, 289, 920-930; PDB identifier 1FFZ).  
U2620 (U2585 in Escherichia coli) is the closest nucleotide to the D-puromycin side 
chain that may cause steric clash.  A2486 (A2451 in E. coli) (yellow), the base possibly 
involved in peptidyl transferase catalysis, is shown for reference.  G2102 (G2481), 
A2103 (A2482), and G2540 (G2505) are the next closest nucleotides (~5Å) to the D-
puromycin side chain. 
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